ClinicalTrials.gg
CompletedNCT00468845Updated Feb 10, 2021Results posted

Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy

A Phase 3 interventional study of pregabalin (Lyrica) and pregabalin (Lyrica) in Pain, Postoperative, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 42 sites in 9 countries. Open to female participants aged 25 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-02-10.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
501
Allocation
Randomized
Ages
25 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 65 studies testing pregabalin in Pain, Postoperative — 7 open to participants now, 7 under way, 1 of them phase 3. Pregabalin · Pain, Postoperative.

Enrollment
Largest of 65
501 · median 90
Started
2007
with 2 others
Phase 3
14 of 65
none open now
Registered
5th of 65
by date
Lead sponsor
5 of 65
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 65 studies testing pregabalin in Pain, Postoperative, this one has the largest enrollment, is one of 3 that started in 2007, is one of 14 in phase 3, and was the 5th registered.

Pain, Postoperative

5,671 studies on the registry are indexed under Pain, Postoperative; 1,241 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

7 of the 65 studies testing pregabalin in Pain, Postoperative are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 677 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 25 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing pregabalin in Pain, Postoperative, or all of them as a file.
02

Study summary

To assess the efficacy of pregabalin compared to placebo on pain following hysterectomy , measured using subject reported assessments of pain.

03

Conditions studied

  • Pain, Postoperative

Browse trials for

Keywords

  • pain after hysterectomy
  • amount of opioids used
04

Who can participate

Ages eligible
25 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject will have elective total abdominal hysterectomy using a transverse incision with or without bilateral salpingo-oophorectomy. The total hysterectomy may, however, be cervix-sparing.
  • The subject is expected to remain at the hospital (or intermediate care facility) for a minimum of 2 days following surgery.
  • The subject's preoperative health is graded as the P1 to P2.

Exclusion criteria

Exclusion Criteria:

  • Subjects having vaginal hysterectomy (whether laparoscopically assisted or not)
  • Subjects having additional procedures (such as those involving the bladder) at the same time as the total abdominal hysterectomy
  • The use of nerve block, spinal anesthesia or epidural anesthesia for post-surgical pain control
  • Subjects who have been using any opioid medications 2 weeks or more continuously within 3 months prior to the screening visit.
  • The subject has taken any NSAID or any analgesic other than acetaminophen within 3 days prior to surgery or is unwilling to abstain from NSAIDs or other analgesics, except as specified in the protocol, during the study. (Subjects taking \<325 mg per day of aspirin at a stable dose for at least 30 days before the first dose of study medication will be allowed to continue their aspirin regimen for the duration of the study).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
501 participants (actual)

Study arms

  • Experimental
    1

    Drug: pregabalin (Lyrica)

  • Experimental
    2

    Drug: pregabalin (Lyrica)

  • Placebo comparator
    3

    Drug: matched placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Worst Pain Using the Modified Brief Pain Inventory - Short Form (m-BPI-sf)

    Modified Brief Pain Inventory - Short Form (m-BPI-sf): participant rated 11-point Likert rating scale ranged from 0 (no pain) to 10 (worst pain imaginable). Least Square (LS) Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: Day 2 (24 hours post surgery [PS])

Secondary outcomes

  1. Current Pain - Pain With Movement Caused by Sitting

    Participant sat upright from supine position, followed by 120 second (sec) rest period, during which participant asked to rate pain with movement. Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. Current pain reported on 11 point Likert scale 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: Day 1 (day of surgery), up to 7 days PS, Discharge, 2 and 4 weeks PS

  2. Current Pain - Pain With Movement Caused by Peak Expiratory (PEF) Test

    Current pain with movement caused by peak expiratory flow (PEF) test as reported by participant on 11 point Likert scale 0 (no pain) to 10 (worst pain). Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. PEF test performed 3 times, with 120sec rest periods in between. At beginning of each rest period, participant asked to rate pain caused by forced expiration. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: Day 1, up to 7 days PS, 2 and 4 weeks PS

  3. Area Under the Curve (AUC) Pain - Pain With Movement Caused by Sitting

    Time-normalized AUC of pain with movement caused by sitting reported by participants. Participant sat upright from supine position, followed by a 120sec rest period, during which the participant asked to rate pain with movement. Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. Current pain reported on 11 point Likert scale 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: 48 +/- 4 hours PS

  4. Area Under the Curve (AUC) Pain - Pain With Movement Caused by Peak Expiratory Flow (PEF) Test

    Time-normalized AUC of pain reported by participants with movement caused by PEF test. Pain reported by participant on 11 point Likert scale 0 (no pain) to 10 (worst pain). PEF test performed 3 times, with 120sec rest periods in between. At beginning of each rest period, participant asked to rate pain caused by forced expiration. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: 48 +/- 4 hours PS

  5. Current Pain at Rest

    Pain reported by participants at rest (numeric rating scale (NRS) - Current Pain) on an 11 point Likert scale 0 (no pain) - 10 (worst pain). Pain at rest during the hospital stay was assessed just before each Pain with Movement assessment. Assessment performed 3 times each day of hospital stay, with 1 of daily assessments at 24 (+/- 2 ) hour intervals from end of surgery. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: 8, 16, 24, 32, 40, 48 hours PS

  6. Area Under the Curve (AUC) of Pain at Rest During the First Two Days of Hospital Stay

    Time-normalized AUC of pain reported by participants on 11 point Likert scale 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: 48 +/- 4 hours PS

  7. Total Cumulative Dose of Opioids Following Surgery

    Total cumulative dose was calculated as milligram (mg) of morphine equivalent and included opioids administered by any route. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: 24, 48 Hours PS, Discharge (day 3 up to day 7 PS)

  8. Integrated Analgesic Score

    The integrated analgesic score (a combination of opioid use and either worst pain, or pain at rest, or pain caused by sitting, or pain caused by forced expiration as defined by Silverman et al 1993) was the sum of percent differences from mean rank for pain and opioids and ranged from -200 to 200 where lower values represent improvement. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: 0-24, 24-48, 48-72 hours PS

  9. Non-opioid Rescue Medication - Paracetamol

    The amounts of non-opioid rescue medications, paracetamol, used by the participants during the study, including anti-emetic medications.

    Time frame: 24, 48, 72 hours PS, Discharge (day 3 up to day 7 PS), Week 1, 2, 3, 4 PS,

  10. Anxiety Before and After Surgery

    Participant anxiety reported on Visual Anxiety Scale (VAS), 0 (not at all anxious) to 100 (extremely anxious). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata

    Time frame: Surgery day before first dose and 1 hour after first dose, Day 1, 2, 3, 4, 5 PS and Discharge (day 3 up to day 7 PS)

  11. Non-opioid Rescue Medication - Ibuprofen

    The amounts of non-opioid rescue medications, ibuprofen, used by the participants during the study, including anti-emetic medications.

    Time frame: 24, 48, 72 hours PS, Discharge (day 3 up to day 7 PS), Week 1, 2, 3, 4 PS

  12. Percent Change From Baseline in Peak Expiratory Flow

    Change from baseline= PEF at x hours minus PEF at baseline; possible values ranged from 0-900 liters/minute (higher values indicated better lung function). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: Baseline, every 8 hours (up to 232 hours) PS, and Discharge (Day 3-7 PS flexible)

  13. Timed Up-and-Go (TUG)

    Functional mobility test performed once a day at 24 hour intervals from surgery after the pain with movement assessment. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: Day 1, 2, 3, 4, 5 PS and Discharge (day 3 up to day 7 PS)

  14. Average Daily Pain

    Post-discharge average pain as measured in daily participant diaries NRS an 11 point Likert scale ranged from 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: Day 2, 3, 4, 5, 6, 7, PS; week 2, 3, 4 PS

  15. Worst Daily Pain

    Post-discharge worst pain as measured in daily participant diaries NRS an 11 point Likert scale that ranged from 0 (no pain) to 10 (pain as bad as you can imagine). LS Means from ANOVA model with terms of treatment, pooled center, salpingo-oophorectomy strata and baseline worst pain score.

    Time frame: Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS

  16. Sleep Interference

    Sleep interference post surgery measured daily in participant diaries; NRS of how pain interfered with sleep during the last 24 hours, ranged from 0 (does not interfere) to 10 (completely interferes). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: Daily post hospital discharge ( Day 2-7 PS), Week 2, 3, 4 PS

  17. Brief Pain Inventory-Short Form (m-BPI-sf): Pain Interference Index Scores

    m-BPI-sf: participant-rated 11 point Likert rating scale ranging from 0 (does not interfere) to 10 (completely interferes) with functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: Baseline, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS

  18. Brief Pain Inventory-Short Form (m-BPI-sf): Pain Severity Index Scores

    m-BPI-sf: participant rated 11-point Likert rating scale ranging from 0 (no pain) to 10 (worst pain possible). Pain severity index is the mean of item scores 2, 3, and 4 (pain right now, worst pain, and average pain level). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: Baseline, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS

  19. Participant Satisfaction With Study Medication - Surgery Day

    Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

    Time frame: Day 1

  20. Participant Satisfaction With Study Medication - Day 1 PS

    Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

    Time frame: Day 1 PS

  21. Participant Satisfaction With Study Medication - Day 2 PS

    Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

    Time frame: Day 2 PS

  22. Participant Satisfaction With Study Medication - Day 3 PS

    Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

    Time frame: Day 3 PS

  23. Participant Satisfaction With Study Medication - Day 4 PS

    Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

    Time frame: Day 4 PS

  24. Participant Satisfaction With Study Medication - Day 5 PS

    Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

    Time frame: Day 5 PS

  25. Participant Satisfaction With Study Medication - Discharge

    Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

    Time frame: Discharge (day 3 up to day 7 PS)

  26. Participant Satisfaction With Study Medication - Day 7 PS

    Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

    Time frame: Day 7 PS

  27. Participant Satisfaction With Study Medication - Day 14 PS

    Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

    Time frame: Day 14 PS

  28. Participant Satisfaction With Study Medication - Day 28 PS

    Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

    Time frame: Day 28 PS

  29. Pain Treatment Satisfaction Scale (PTSS): Satisfaction With Current Pain Medication

    Satisfaction with current pain medication ranged from 0 (worst possible response) to100 (best possible response). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: Discharge (day 3 up to day 7 PS), Day 28 PS

  30. Pain Treatment Satisfaction Scale (PTSS): Impact of Current Pain Medication

    Impact of current pain medication response scale: 0 (worst possible response) to 100 (best possible response). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: Discharge (day 3 up to day 7 PS), Day 28 PS

  31. Quality of Life Using EuroQol (EQ-5D) Health State Profile

    Participant rated questionnaire assessed current health for 6 domains: mobility/self-care/ usual activities/pain/discomfort/anxiety and depression. Scoring developed by EuroQol Group assigned a utility value for each domain in the profile. Scores ranged from 1 better health (no problems) to 3 worst health (eg, "confined to bed"). Score transformed and resulted in a total score range -0.594 to 1.000; higher score=better health state. Health profile scores estimated using Dolan computational algorithms 1997 and 2001. LS Means adjusted for treatment/pooled center/salpingo-oophorectomy strata.

    Time frame: Discharge (day 3 up to day 7 PS) and day 28 PS

  32. Time to Meet Hospital Discharge Criteria

    Mean time from end of surgery to meet protocol defined hospital discharge criteria: participant no longer received parental opioids, was able to dress and mobilize without assistance, and had normal intake of food and fluids.

    Time frame: Day 1 up to Day 7 PS

  33. Time to Actual Discharge

    Mean time from end of surgery to actual hospital discharge. Participant was expected to remain at the hospital for a minimum of 2 days following surgery.

    Time frame: Day 1 up to Day 7 PS

  34. Incidence of Chronic Post-operative Pain

    Chronic post-operative pain as a result of abdominal hysterectomy as reported by participants on PS questionaire of pain within last 24 hours in area affected by surgery.

    Time frame: 3 and 6 Months PS

  35. Total Clinically Meaningful Event (CME) Score

    Total CME score calculated by summing the number of Clinically Meaningful Events (CMEs) across symptoms. CME for each symptom will be defined using the Opioid-Related Symptom Distress Scale (OR-SDS) a participant rated scale of symptoms within the last 24 hours. Total CME score could range from 0 to 9. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: Surgery Day, Day 1, 2, 3, 4, 5 PS, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS

Other outcomes

  1. Percentage of Participants With Wound Healing Complications - Discharge

    Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.

    Time frame: Discharge (day 3 up to day 7 PS)

  2. Percentage of Participants With Wound Healing Complications - Day 7 PS

    Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.

    Time frame: Day 7 PS

  3. Percentage of Participants With Wound Healing Complications - Day 14 PS

    Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.

    Time frame: Day 14 PS

  4. Percentage of Participants With Wound Healing Complications - Day 28 PS

    Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.

    Time frame: Day 28 PS

  5. Percentage of Participants With Wound Healing Complications - End of Treatment

    Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.

    Time frame: Day 1 up to Day 28 PS

  6. Incision Length Correlated With Worst Pain

    Incision length (cm) correlated with worst pain. Worst pain ranged from 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center, salpingo-oophorectomy strata.

    Time frame: Day 1

  7. Neuropathic Pain Symptom Inventory (NPSI)

    Pain characteristics in participants who reported pain (mBPI-sf, NPSI); NPSI a participant rated questionnaire to evaluate different symptoms of neuropathic pain, burning spontaneous pain, pressing spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia at discharge. NPSI Total Score ranged from 0 to 0.5; NPSI subscales pain ranged from 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

    Time frame: Discharge (day 3 up to day 7 PS)

07

Results

Posted May 26, 2011

Participant flow

Participant flow — Overall Study
MilestonePregabalin 150mgPregabalin 300 mgPlacebo
Started162170169
Received treatment161166167
Completed141136139
Not completed213430
Withdrew: Adverse event91411
Withdrew: Lost to follow-up212
Withdrew: Other495
Withdrew: No longer willing to participate5610
Withdrew: Randomized, not treated142

Outcome measures

PrimaryWorst Pain Using the Modified Brief Pain Inventory - Short Form (m-BPI-sf)

Modified Brief Pain Inventory - Short Form (m-BPI-sf): participant rated 11-point Likert rating scale ranged from 0 (no pain) to 10 (worst pain imaginable). Least Square (LS) Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
Day 2 (24 hours post surgery [PS])
Reported as:
Least squares mean · Units on a scale
Worst Pain Using the Modified Brief Pain Inventory - Short Form (m-BPI-sf)
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
Worst Pain Using the Modified Brief Pain Inventory - Short Form (m-BPI-sf)7.1 ± 0.187.2 ± 0.187.4 ± 0.18
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.1378 (Weighted Z-score test method of Fisher (1998) and Cui et al (1999)applied to maintain alpha level. A step down procedure for multiple comparisons to control the maximum experiment wise type I error rate at 0.05 level. 300mg tested prior to 150mg.)
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.4710 (Weighted Z-score test method of Fisher (1998) and Cui et al (1999)applied to maintain alpha level. A step down procedure for multiple comparisons to control the maximum experiment wise type I error rate at 0.05 level. 300mg tested prior to 150mg.)
SecondaryCurrent Pain - Pain With Movement Caused by Sitting

Participant sat upright from supine position, followed by 120 second (sec) rest period, during which participant asked to rate pain with movement. Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. Current pain reported on 11 point Likert scale 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
Day 1 (day of surgery), up to 7 days PS, Discharge, 2 and 4 weeks PS
Reported as:
Least squares mean · Units on a scale
Current Pain - Pain With Movement Caused by Sitting
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
24 Hours PS (n=147, 141, 149)5.21 ± 0.1885.53 ± 0.1945.28 ± 0.189
48 Hours PS (n=142, 141, 142)3.57 ± 0.1853.71 ± 0.1893.67 ± 0.189
72 Hours PS (n=83, 90, 75)2.80 ± 0.2393.04 ± 0.2253.20 ± 0.257
96 Hours PS (n=29, 31, 26)2.31 ± 0.4253.20 ± 0.3833.20 ± 0.444
120 Hours PS (n=14, 15, 12)2.89 ± 0.5842.84 ± 0.5272.36 ± 0.633
144 Hours PS (n=2, 5, 5)1.86 ± 1.4961.26 ± 1.1772.00 ± 1.010
Discharge (n=141, 135, 144)2.67 ± 0.1752.99 ± 0.1812.42 ± 0.176
Day 14 (n=126, 120, 128)1.08 ± 0.1401.37 ± 0.1451.30 ± 0.143
Day 28 (n=138, 138, 142)0.70 ± 0.1260.91 ± 0.1290.76 ± 0.127
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.7752LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.3375LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.7029LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.8618LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2117LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.6255LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.0942LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.9907LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.4678LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.5500LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.9333LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.7396LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2932LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.0164LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2468LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.7022LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.7257LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.3854LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryCurrent Pain - Pain With Movement Caused by Peak Expiratory (PEF) Test

Current pain with movement caused by peak expiratory flow (PEF) test as reported by participant on 11 point Likert scale 0 (no pain) to 10 (worst pain). Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. PEF test performed 3 times, with 120sec rest periods in between. At beginning of each rest period, participant asked to rate pain caused by forced expiration. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
Day 1, up to 7 days PS, 2 and 4 weeks PS
Reported as:
Least squares mean · Units on a scale
Current Pain - Pain With Movement Caused by Peak Expiratory (PEF) Test
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
24 hours PS (n=146, 142, 148)4.83 ± 0.2024.92 ± 0.2094.97 ± 0.207
48 hours PS (n=141, 143, 140)3.22 ± 0.2043.47 ± 0.2053.46 ± 0.210
72 hours PS (n=83, 90, 74)2.62 ± 0.2422.69 ± 0.2283.04 ± 0.263
96 hours PS (n=28, 31, 25)1.88 ± 0.4653.05 ± 0.4143.28 ± 0.487
120 hours PS (n=13, 14, 11)1.97 ± 0.6852.10 ± 0.6091.45 ± 0.740
144 hours PS (n=2, 5, 3)3.67 ± 2.4720.67 ± 1.4531.67 ± 1.764
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.5997LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.8582LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.3704LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.9747LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2033LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.2752LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.0183LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.6906LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.5446LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.4852LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.5879LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.7699LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryArea Under the Curve (AUC) Pain - Pain With Movement Caused by Sitting

Time-normalized AUC of pain with movement caused by sitting reported by participants. Participant sat upright from supine position, followed by a 120sec rest period, during which the participant asked to rate pain with movement. Assessment performed 3 times each day of hospital stay, with 1 daily assessment at 24 (+/- 2) hour interval from end of surgery. Current pain reported on 11 point Likert scale 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
48 +/- 4 hours PS
Reported as:
Least squares mean · Units on a scale
Area Under the Curve (AUC) Pain - Pain With Movement Caused by Sitting
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
Area Under the Curve (AUC) Pain - Pain With Movement Caused by Sitting4.87 ± 0.1555.01 ± 0.1614.87 ± 0.157
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.9676LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.4944LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryArea Under the Curve (AUC) Pain - Pain With Movement Caused by Peak Expiratory Flow (PEF) Test

Time-normalized AUC of pain reported by participants with movement caused by PEF test. Pain reported by participant on 11 point Likert scale 0 (no pain) to 10 (worst pain). PEF test performed 3 times, with 120sec rest periods in between. At beginning of each rest period, participant asked to rate pain caused by forced expiration. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
48 +/- 4 hours PS
Reported as:
Least squares mean · Units on a scale
Area Under the Curve (AUC) Pain - Pain With Movement Caused by Peak Expiratory Flow (PEF) Test
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
Area Under the Curve (AUC) Pain - Pain With Movement Caused by Peak Expiratory Flow (PEF) Test4.45 ± 0.1674.64 ± 0.1744.61 ± 0.173
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.4801LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.8832LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryCurrent Pain at Rest

Pain reported by participants at rest (numeric rating scale (NRS) - Current Pain) on an 11 point Likert scale 0 (no pain) - 10 (worst pain). Pain at rest during the hospital stay was assessed just before each Pain with Movement assessment. Assessment performed 3 times each day of hospital stay, with 1 of daily assessments at 24 (+/- 2 ) hour intervals from end of surgery. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
8, 16, 24, 32, 40, 48 hours PS
Reported as:
Least squares mean · Units on a scale
Current Pain at Rest
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
8 Hours PS (n=123, 125, 126)5.13 ± 0.2325.39 ± 0.2315.47 ± 0.225
16 Hours PS (n=94, 88, 107)4.06 ± 0.2564.55 ± 0.2734.30 ± 0.245
24 Hours PS (n=151, 147, 154)3.79 ± 0.1793.76 ± 0.1843.93 ± 0.180
32 Hours PS (n=127, 127, 136)3.37 ± 0.2073.31 ± 0.2123.55 ± 0.204
40 Hours PS (n=93, 97, 100)2.97 ± 0.2652.71 ± 0.2652.98 ± 0.263
48 Hours PS (n=142, 143, 140)2.60 ± 0.1732.26 ± 0.1742.65 ± 0.179
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2125LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.7602LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.4053LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.4147LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.5556LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.4820LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.5088LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.3900LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.9659LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.3968LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.8308LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.0902LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryArea Under the Curve (AUC) of Pain at Rest During the First Two Days of Hospital Stay

Time-normalized AUC of pain reported by participants on 11 point Likert scale 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
48 +/- 4 hours PS
Reported as:
Least squares mean · Units on a scale
Area Under the Curve (AUC) of Pain at Rest During the First Two Days of Hospital Stay
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
Area Under the Curve (AUC) of Pain at Rest During the First Two Days of Hospital Stay3.62 ± 0.1433.58 ± 0.1473.76 ± 0.144
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.4388LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.3364LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryTotal Cumulative Dose of Opioids Following Surgery

Total cumulative dose was calculated as milligram (mg) of morphine equivalent and included opioids administered by any route. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
24, 48 Hours PS, Discharge (day 3 up to day 7 PS)
Reported as:
Least squares mean · milligram (mg)
Total Cumulative Dose of Opioids Following Surgery
milligram (mg)Pregabalin 150mgPregabalin 300 mgPlacebo
24 hours PS (n=150, 147, 153)113.38 ± 7.078111.27 ± 7.211124.44 ± 7.160
48 hours PS (n=150, 147, 151)148.67 ± 9.218144.95 ± 9.391168.31 ± 9.372
Till Discharge (n=147, 143, 144)164.28 ± 11.161167.01 ± 11.410195.32 ± 11.569
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2409LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1654LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.1110LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.0598LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.0398LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.0623LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryIntegrated Analgesic Score

The integrated analgesic score (a combination of opioid use and either worst pain, or pain at rest, or pain caused by sitting, or pain caused by forced expiration as defined by Silverman et al 1993) was the sum of percent differences from mean rank for pain and opioids and ranged from -200 to 200 where lower values represent improvement. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
0-24, 24-48, 48-72 hours PS
Reported as:
Least squares mean · Units on a scale
Integrated Analgesic Score
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
0-24 Hours PS (n=150, 145, 151)-6.58 ± 6.795-11.66 ± 6.9913.36 ± 6.906
24-48 Hours PS (n=141, 142, 139)-5.51 ± 6.979-18.84 ± 7.0515.48 ± 7.210
48-72 Hours PS (n=81, 89, 74)3.23 ± 9.884-6.93 ± 9.27119.85 ± 10.568
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2730LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1015LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2438LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.0102LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2063LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.0387LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryNon-opioid Rescue Medication - Paracetamol

The amounts of non-opioid rescue medications, paracetamol, used by the participants during the study, including anti-emetic medications.

Time frame:
24, 48, 72 hours PS, Discharge (day 3 up to day 7 PS), Week 1, 2, 3, 4 PS,
Reported as:
Mean · Grams (g)
Non-opioid Rescue Medication - Paracetamol
Grams (g)Pregabalin 150mgPregabalin 300 mgPlacebo
24 Hours PS (n=150, 147, 155)1.16 ± 0.0981.21 ± 0.1001.22 ± 0.098
48 Hours PS (n=150, 147, 154)3.23 ± 0.1953.20 ± 0.1993.55 ± 0.195
72 Hours PS (n=150, 147,149)5.07 ± 0.2945.08 ± 0.3005.68 ± 0.301
1st Week PS (n=142, 142, 145)10.76 ± 0.73210.57 ± 0.73912.63 ± 0.740
2nd Week PS (n=139, 135, 143)17.89 ± 1.71116.79 ± 1.74719.70 ± 1.731
3rd Week PS (n=131, 124, 134)23.56 ± 2.65422.12 ± 2.74824.35 ± 2.695
4th Week PS (n=95, 94, 103)27.10 ± 3.31325.62 ± 3.43725.63 ± 3.301
Till Discharge (n=147, 143, 147)5.45 ± 0.3905.78 ± 0.3996.05 ± 0.399
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.5995LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.9104LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2177LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1770LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.1229LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1274LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.0568LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.0354LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.4269LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.2058LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.8215LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.5331LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.7365LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.9989LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2501LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.6021LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryAnxiety Before and After Surgery

Participant anxiety reported on Visual Anxiety Scale (VAS), 0 (not at all anxious) to 100 (extremely anxious). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata

Time frame:
Surgery day before first dose and 1 hour after first dose, Day 1, 2, 3, 4, 5 PS and Discharge (day 3 up to day 7 PS)
Reported as:
Least squares mean · Units on a scale
Anxiety Before and After Surgery
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
Surgery Day (prior to first dose)(n=149, 144, 151)31.9 ± 2.3828.4 ± 2.4533.3 ± 2.40
Surgery Day (1 hour after dosing)(n=138, 139, 146)29.5 ± 2.3929.7 ± 2.3930.9 ± 2.38
Day 1 PS (n=150, 149, 154)15.6 ± 1.7516.1 ± 1.7818.6 ± 1.77
Day 2 PS (n=112, 120, 118)12.6 ± 2.0513.4 ± 1.9813.8 ± 2.03
Day 3 PS (n=44, 40, 35)17.2 ± 3.1711.2 ± 2.9313.9 ± 3.20
Day 4 PS (n=17, 20, 15)9.0 ± 3.224.2 ± 2.729.3 ± 3.51
Day 5 PS (n=7, 13, 7)11.6 ± 8.314.5 ± 5.3915.1 ± 8.46
Discharge (n=143, 144, 148)10.2 ± 1.508.3 ± 1.508.8 ± 1.50
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.6613LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1311LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.6574LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.6949LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2008LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.3022LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.6382LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.8624LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.3858LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.4814LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.9520LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.2315LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.7061LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.2908LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.4782LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.8130LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryNon-opioid Rescue Medication - Ibuprofen

The amounts of non-opioid rescue medications, ibuprofen, used by the participants during the study, including anti-emetic medications.

Time frame:
24, 48, 72 hours PS, Discharge (day 3 up to day 7 PS), Week 1, 2, 3, 4 PS
Reported as:
Mean · Grams (g)
Non-opioid Rescue Medication - Ibuprofen
Grams (g)Pregabalin 150mgPregabalin 300 mgPlacebo
24 Hours PS (n=150, 147, 155)0.01 ± 0.0140.03 ± 0.0140.01 ± 0.014
48 Hours PS (n=150, 147, 154)0.08 ± 0.0370.15 ± 0.0380.12 ± 0.038
72 Hours PS (n=150, 147, 149)0.14 ± 0.0640.27 ± 0.0650.24 ± 0.066
1st Week PS (n=142, 142, 145)0.51 ± 0.2080.87 ± 0.2100.97 ± 0.211
2nd Week PS (n=140, 135, 143)1.22 ± 0.4131.94 ± 0.4231.88 ± 0.420
3rd Week PS (n=132, 124, 134)1.95 ± 0.6652.99 ± 0.6922.83 ± 0.679
4th Week PS (n=95, 94, 103)2.42 ± 1.0414.30 ± 1.0803.84 ± 1.038
Till Discharge (n=147, 143, 147)0.18 ± 0.0740.38 ± 0.0760.26 ± 0.076
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.8940LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.5938LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.4306LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.5899LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2209LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.7145LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.1022LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.7243LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2310LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.9192LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.3214LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.8641LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.3024LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.7359LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.4303LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.2133LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryPercent Change From Baseline in Peak Expiratory Flow

Change from baseline= PEF at x hours minus PEF at baseline; possible values ranged from 0-900 liters/minute (higher values indicated better lung function). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
Baseline, every 8 hours (up to 232 hours) PS, and Discharge (Day 3-7 PS flexible)
Reported as:
Least squares mean · L/min
Percent Change From Baseline in Peak Expiratory Flow
L/minPregabalin 150mgPregabalin 300 mgPlacebo
Baseline (n=116, 114, 121)0 ± 00 ± 00 ± 0
8 Hours PS (n=84, 79, 83)-39.25 ± 3.081-35.35 ± 3.307-41.29 ± 3.242
16 Hours PS (n=72, 62, 76)-37.37 ± 3.454-36.49 ± 3.764-36.48 ± 3.395
24 Hours PS (n=115, 112, 117)-28.92 ± 3.084-26.53 ± 3.212-29.46 ± 3.058
32 Hours PS (n=104, 105, 106)-24.53 ± 3.510-25.66 ± 3.644-28.92 ± 3.632
40 Hours PS (n=70, 73, 79)-24.18 ± 3.575-25.70 ± 3.663-25.07 ± 3.449
48 Hours PS (n=108, 112, 111)-16.71 ± 3.203-13.62 ± 3.255-21.70 ± 3.162
56 Hours PS (n=78, 85, 82)-17.11 ± 3.760-15.40 ± 3.771-21.12 ± 3.726
64 Hours PS (n=52, 51, 54)-15.04 ± 4.672-14.20 ± 5.028-17.18 ± 4.392
72 Hours PS (n=61, 68, 60)-18.12 ± 5.270-12.97 ± 4.792-20.81 ± 5.059
80 Hours PS (n=30, 24, 24)-17.23 ± 7.290-3.01 ± 7.750-8.17 ± 7.443
88 Hours PS (n=18, 15, 19)-10.08 ± 8.257-2.30 ± 8.818-9.71 ± 6.636
96 Hours PS (n=20, 22, 21)-1.45 ± 9.0635.26 ± 8.5852.36 ± 9.110
104 Hours PS (n=9, 12, 12)-12.79 ± 10.5740.69 ± 9.428-4.94 ± 10.210
112 Hours PS (n=5, 10, 9)-15.61 ± 15.6298.49 ± 10.863-11.61 ± 10.700
120 Hours PS (n=10, 12, 10)-12.36 ± 11.386-8.14 ± 10.307-6.98 ± 12.201
128 Hours PS (n=4, 9, 7)-6.72 ± 13.735-4.76 ± 8.166-14.32 ± 10.711
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.5682LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1005LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.8261LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.9981LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.8884LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.4507LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2994LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.4371LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.8295LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.8783LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2161LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.0440LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.3855LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.2010LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.7104LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.6107LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.6705LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.2083LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.3234LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.5938LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.9711LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.4869LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.7439LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.8045LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.5925LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.6830LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.8266LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1929LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.7071LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.9367LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.6046LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.5119LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryTimed Up-and-Go (TUG)

Functional mobility test performed once a day at 24 hour intervals from surgery after the pain with movement assessment. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
Day 1, 2, 3, 4, 5 PS and Discharge (day 3 up to day 7 PS)
Reported as:
Least squares mean · Seconds
Timed Up-and-Go (TUG)
SecondsPregabalin 150mgPregabalin 300 mgPlacebo
Day 1 PS (n=85, 85, 93)39.77 ± 2.55842.79 ± 2.76938.54 ± 2.611
Day 2 PS (n=107, 105, 105)31.82 ± 1.77633.06 ± 1.87829.25 ± 1.845
Day 3 PS (n=43, 35, 31)34.07 ± 2.77933.48 ± 2.78131.38 ± 2.960
Day 4 PS (n=16, 18, 13)42.26 ± 4.59137.31 ± 4.06540.43 ± 5.275
Day 5 PS (n=7, 10, 7)31.27 ± 5.29523.06 ± 3.70432.18 ± 5.326
Discharge (n=130, 134, 134)28.11 ± 1.60430.05 ± 1.56926.40 ± 1.582
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.6966LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1808LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2616LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1014LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.4401LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.5615LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.7615LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.6204LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.8766LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1717LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.4065LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.0746LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryAverage Daily Pain

Post-discharge average pain as measured in daily participant diaries NRS an 11 point Likert scale ranged from 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
Day 2, 3, 4, 5, 6, 7, PS; week 2, 3, 4 PS
Reported as:
Least squares mean · Units on a scale
Average Daily Pain
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
Day 2 PS (n=29, 21, 25)3.9 ± 0.484.3 ± 0.553.1 ± 0.59
Day 3 PS (n=97, 94, 98)3.0 ± 0.223.2 ± 0.232.8 ± 0.23
Day 4 PS (n=126, 114, 125)2.7 ± 0.192.9 ± 0.212.8 ± 0.20
Day 5 PS (n=133, 117, 133)2.5 ± 0.182.6 ± 0.202.6 ± 0.19
Day 6 PS (n=133, 125, 138)2.3 ± 0.182.5 ± 0.192.4 ± 0.18
Day 7 PS (n=132, 130, 135)2.1 ± 0.172.3 ± 0.172.2 ± 0.17
2nd Week PS (Average) (n=134, 131, 139)1.7 ± 0.142.0 ± 0.141.7 ± 0.14
3rd Week PS (Average) (n=114, 110, 114)1.3 ± 0.151.7 ± 0.151.3 ± 0.16
4th Week PS (Average) (n=87, 87, 82)1.2 ± 0.181.6 ± 0.191.2 ± 0.20
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2201LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.0606LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.5303LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.2227LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.8237LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.7476LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.6882LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.9689LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.5010LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.9143LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.7381LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.5336LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.6479LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1133LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.7637LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1056LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.8079LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.0917LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryWorst Daily Pain

Post-discharge worst pain as measured in daily participant diaries NRS an 11 point Likert scale that ranged from 0 (no pain) to 10 (pain as bad as you can imagine). LS Means from ANOVA model with terms of treatment, pooled center, salpingo-oophorectomy strata and baseline worst pain score.

Time frame:
Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS
Reported as:
Mean · Units on a scale
Worst Daily Pain
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
Discharge (n=140, 143, 138)4.3 ± 0.224.4 ± 0.224.2 ± 0.22
Day 7 (n=123, 121, 125)3.2 ± 0.243.4 ± 0.243.5 ± 0.23
Day 14 (n=129, 125, 130)1.8 ± 0.192.4 ± 0.192.5 ± 0.19
Day 28 (n=141, 142, 143)1.2 ± 0.151.7 ± 0.151.4 ± 0.15
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.7511LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.6742LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.3808LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.7021LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.0045LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.7916LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.3682LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1419LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondarySleep Interference

Sleep interference post surgery measured daily in participant diaries; NRS of how pain interfered with sleep during the last 24 hours, ranged from 0 (does not interfere) to 10 (completely interferes). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
Daily post hospital discharge ( Day 2-7 PS), Week 2, 3, 4 PS
Reported as:
Least squares mean · Units on a scale
Sleep Interference
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
Day 2 PS (n=21, 18, 20)2.4 ± 0.653.6 ± 0.673.2 ± 0.77
Day 3 PS (n=88, 89, 87)2.6 ± 0.322.3 ± 0.332.6 ± 0.33
Day 4 PS (n=122, 111, 119)2.3 ± 0.242.5 ± 0.272.5 ± 0.26
Day 5 PS (n=133, 117, 132)2.1 ± 0.222.2 ± 0.242.5 ± 0.22
Day 6 PS (n=133, 127, 138)1.7 ± 0.221.9 ± 0.232.1 ± 0.22
Day 7 PS (n=132, 131, 138)1.7 ± 0.222.0 ± 0.222.1 ± 0.22
2nd Week PS (Average) (n=134, 131, 139)1.3 ± 0.161.7 ± 0.171.5 ± 0.16
3rd Week PS (Average) (n=115, 112, 113)1.0 ± 0.161.3 ± 0.161.0 ± 0.17
4th Week PS (Average) (n=87, 87, 81)1.0 ± 0.211.4 ± 0.210.9 ± 0.22
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.3323LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.5662LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.9538LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.4592LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.4793LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.8517LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.1829LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.3544LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.1718LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.5078LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2443LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.8296LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.3243LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.3755LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.9584LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1187LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.7915LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.0703LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryBrief Pain Inventory-Short Form (m-BPI-sf): Pain Interference Index Scores

m-BPI-sf: participant-rated 11 point Likert rating scale ranging from 0 (does not interfere) to 10 (completely interferes) with functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
Baseline, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS
Reported as:
Least squares mean · Units on a scale
Brief Pain Inventory-Short Form (m-BPI-sf): Pain Interference Index Scores
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
Baseline (n=149, 147, 154)0 ± 00 ± 00 ± 0
Discharge (n=133, 131, 130)2.57 ± 0.1942.62 ± 0.1982.90 ± 0.200
Day 7 (n=121, 119, 123)1.96 ± 0.2012.09 ± 0.2062.52 ± 0.198
Day 28 (n=140, 141, 142)0.85 ± 0.1221.01 ± 0.1221.07 ± 0.123
Day 14 (n=129, 123, 126)1.20 ± 0.1481.41 ± 0.1521.68 ± 0.152
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.1975LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.2784LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.0271LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.0881LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.0159LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1870LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.1752LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.6923LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
Other pre-specifiedPercentage of Participants With Wound Healing Complications - Discharge

Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.

Time frame:
Discharge (day 3 up to day 7 PS)
Reported as:
Number · Percentage of participants
Percentage of Participants With Wound Healing Complications - Discharge
Percentage of participantsPregabalin 150mgPregabalin 300 mgPlacebo
Superficial Incision SSI3.11.20.6
Deep Incision SSI000
Organ/space SSI000
Non-infectious Wound Healing01.20
Other pre-specifiedPercentage of Participants With Wound Healing Complications - Day 7 PS

Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.

Time frame:
Day 7 PS
Reported as:
Number · Percentage of participants
Percentage of Participants With Wound Healing Complications - Day 7 PS
Percentage of participantsPregabalin 150mgPregabalin 300 mgPlacebo
Superficial Incision SSI1.92.50.6
Deep Incision SSI0.600
Organ/space SSI000
Non-infectious Wound Healing3.81.90.6
SecondaryBrief Pain Inventory-Short Form (m-BPI-sf): Pain Severity Index Scores

m-BPI-sf: participant rated 11-point Likert rating scale ranging from 0 (no pain) to 10 (worst pain possible). Pain severity index is the mean of item scores 2, 3, and 4 (pain right now, worst pain, and average pain level). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
Baseline, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS
Reported as:
Least squares mean · Units on a scale
Brief Pain Inventory-Short Form (m-BPI-sf): Pain Severity Index Scores
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
Baseline (n=149, 147, 155)0 ± 00 ± 00 ± 0
Discharge (n=140, 141, 138)2.62 ± 0.1372.60 ± 0.1372.53 ± 0.141
Day 7 (n=122, 121, 125)2.05 ± 0.1722.16 ± 0.1772.20 ± 0.169
Day 14 (n=129, 124, 130)1.19 ± 0.1371.63 ± 0.1421.61 ± 0.138
Day 28 (n=141, 142, 143)0.79 ± 0.1100.98 ± 0.1100.83 ± 0.110
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.6295LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.6890LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.5094LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.8741LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.0214LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.9366LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.7833LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.2983LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
Other pre-specifiedPercentage of Participants With Wound Healing Complications - Day 14 PS

Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.

Time frame:
Day 14 PS
Reported as:
Number · Percentage of participants
Percentage of Participants With Wound Healing Complications - Day 14 PS
Percentage of participantsPregabalin 150mgPregabalin 300 mgPlacebo
Superficial Incision SSI5.02.52.4
Deep Incision SSI0.600
Organ/space SSI0.600
Non-infectious Wound Healing4.42.50.6
Other pre-specifiedPercentage of Participants With Wound Healing Complications - Day 28 PS

Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.

Time frame:
Day 28 PS
Reported as:
Number · Percentage of participants
Percentage of Participants With Wound Healing Complications - Day 28 PS
Percentage of participantsPregabalin 150mgPregabalin 300 mgPlacebo
Superficial Incision SSI1.91.91.2
Deep Incision SSI000
Organ/space SSI000.6
Non-infectious Wound Healing2.52.50
SecondaryParticipant Satisfaction With Study Medication - Surgery Day

Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

Time frame:
Day 1
Reported as:
Number · Percentage of participants
Participant Satisfaction With Study Medication - Surgery Day
Percentage of participantsPregabalin 150mgPregabalin 300 mgPlacebo
Excellent14.33.120.0
Good42.962.535.0
Fair39.331.330.0
Poor3.63.115.0
Statistical analysis
  • Pregabalin 150mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.6861Cochran-Mantel-Haenszel (CMH) test adjusted for pooled centers and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.9905CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
SecondaryParticipant Satisfaction With Study Medication - Day 1 PS

Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

Time frame:
Day 1 PS
Reported as:
Number · Percentage of participants
Participant Satisfaction With Study Medication - Day 1 PS
Percentage of participantsPregabalin 150mgPregabalin 300 mgPlacebo
Excellent13.317.616.2
Good56.047.345.5
Fair26.729.130.5
Poor4.06.17.8
Statistical analysis
  • Pregabalin 150mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.4264CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3045CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
SecondaryParticipant Satisfaction With Study Medication - Day 2 PS

Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

Time frame:
Day 2 PS
Reported as:
Number · Percentage of participants
Participant Satisfaction With Study Medication - Day 2 PS
Percentage of participantsPregabalin 150mgPregabalin 300 mgPlacebo
Excellent21.917.616.2
Good49.154.647.0
Fair25.421.829.1
Poor3.55.97.7
Statistical analysis
  • Pregabalin 150mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0714CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.4455CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
SecondaryParticipant Satisfaction With Study Medication - Day 3 PS

Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

Time frame:
Day 3 PS
Reported as:
Number · Percentage of participants
Participant Satisfaction With Study Medication - Day 3 PS
Percentage of participantsPregabalin 150mgPregabalin 300 mgPlacebo
Excellent15.917.517.6
Good52.347.550.0
Fair31.830.029.4
Poor05.02.9
Statistical analysis
  • Pregabalin 150mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.7418CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.5154CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
SecondaryParticipant Satisfaction With Study Medication - Day 4 PS

Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

Time frame:
Day 4 PS
Reported as:
Number · Percentage of participants
Participant Satisfaction With Study Medication - Day 4 PS
Percentage of participantsPregabalin 150mgPregabalin 300 mgPlacebo
Excellent17.65.314.3
Good52.957.942.9
Fair29.431.628.6
Poor05.314.3
Statistical analysis
  • Pregabalin 150mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.6715CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.9013CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
SecondaryParticipant Satisfaction With Study Medication - Day 5 PS

Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

Time frame:
Day 5 PS
Reported as:
Number · Percentage of participants
Participant Satisfaction With Study Medication - Day 5 PS
Percentage of participantsPregabalin 150mgPregabalin 300 mgPlacebo
Excellent07.714.3
Good71.453.842.9
Fair28.638.528.6
Poor0014.3
Statistical analysis
  • Pregabalin 150mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.9126CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 1.0000CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
SecondaryParticipant Satisfaction With Study Medication - Discharge

Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

Time frame:
Discharge (day 3 up to day 7 PS)
Reported as:
Number · Percentage of participants
Participant Satisfaction With Study Medication - Discharge
Percentage of participantsPregabalin 150mgPregabalin 300 mgPlacebo
Excellent29.626.226.4
Good48.651.039.9
Fair16.917.925.0
Poor4.94.88.8
Statistical analysis
  • Pregabalin 150mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1233CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1666CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
SecondaryParticipant Satisfaction With Study Medication - Day 7 PS

Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

Time frame:
Day 7 PS
Reported as:
Number · Percentage of participants
Participant Satisfaction With Study Medication - Day 7 PS
Percentage of participantsPregabalin 150mgPregabalin 300 mgPlacebo
Excellent36.636.925.2
Good38.237.739.4
Fair15.417.226.0
Poor9.88.29.4
Statistical analysis
  • Pregabalin 150mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0361CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0797CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
SecondaryParticipant Satisfaction With Study Medication - Day 14 PS

Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

Time frame:
Day 14 PS
Reported as:
Number · Percentage of participants
Participant Satisfaction With Study Medication - Day 14 PS
Percentage of participantsPregabalin 150mgPregabalin 300 mgPlacebo
Excellent40.042.931.3
Good42.337.333.6
Fair11.516.724.4
Poor6.23.210.7
Statistical analysis
  • Pregabalin 150mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0206CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0011CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
Other pre-specifiedPercentage of Participants With Wound Healing Complications - End of Treatment

Pre-specified adverse events of wound healing complications based on Center for Disease Control and Prevention, 1999, guidelines for prevention of surgical site infection (SSI) wound healing complications included: superficial incisional SSI, deep incisional SSI, organ/space SSI or non-infections wound healing complication.

Time frame:
Day 1 up to Day 28 PS
Reported as:
Number · Percentage of participants
Percentage of Participants With Wound Healing Complications - End of Treatment
Percentage of participantsPregabalin 150mgPregabalin 300 mgPlacebo
Superficial Incision SSI01.20
Deep Incision SSI000
Organ/space SSI000
Non-infectious Wound Healing000
Other pre-specifiedIncision Length Correlated With Worst Pain

Incision length (cm) correlated with worst pain. Worst pain ranged from 0 (no pain) to 10 (worst pain imaginable). LS Means adjusted for treatment, pooled center, salpingo-oophorectomy strata.

Time frame:
Day 1
Reported as:
Least squares mean · Centimeter (cm)
Incision Length Correlated With Worst Pain
Centimeter (cm)Pregabalin 150mgPregabalin 300 mgPlacebo
Incision Length Correlated With Worst Pain7.1074 ± 0.20107.2324 ± 0.19667.4437 ± 0.1977
Statistical analysis
  • Pregabalin 150mg vs Pregabalin 300 mg vs Placebo · ANOVA · p = 0.3506LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryParticipant Satisfaction With Study Medication - Day 28 PS

Participant satisfaction with study medication using the Global Evaluation of Study Medication questionaire. Participants overall impression (global evaluation) of the study medication was recorded by the participant by answering the following question: How would you rate the study medication you received for pain? Excellent 4; Good 3; Fair 2; Poor 1.

Time frame:
Day 28 PS
Reported as:
Number · Percentage of participants
Participant Satisfaction With Study Medication - Day 28 PS
Percentage of participantsPregabalin 150mgPregabalin 300 mgPlacebo
Excellent42.440.134.3
Good41.734.535.0
Fair9.416.223.8
Poor6.59.27.0
Statistical analysis
  • Pregabalin 150mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0287CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2270CMH test adjusted for pooled centers and salpingo-oophorectomy strata.
SecondaryPain Treatment Satisfaction Scale (PTSS): Satisfaction With Current Pain Medication

Satisfaction with current pain medication ranged from 0 (worst possible response) to100 (best possible response). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
Discharge (day 3 up to day 7 PS), Day 28 PS
Reported as:
Least squares mean · Units on a scale
Pain Treatment Satisfaction Scale (PTSS): Satisfaction With Current Pain Medication
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
Medication Subscale/Discharge (n=138, 137, 139)79.43 ± 1.71778.45 ± 1.74776.71 ± 1.776
Medication Subscale/Day 28 (n=133, 134, 137)82.52 ± 1.61980.16 ± 1.60178.26 ± 1.615
Characteristic Subscale/Discharge (n=138,136,138)82.15 ± 1.56581.88 ± 1.59779.58 ± 1.623
Characteristic Subscale/Day 28 (n=133, 133, 137)84.82 ± 1.44883.16 ± 1.43881.69 ± 1.445
Efficacy Subscale/Discharge (n=138, 137, 139)76.68 ± 2.26475.04 ± 2.30473.77 ± 2.342
Efficacy Subscale/Day 28 (n=133, 134, 136)80.20 ± 2.16176.92 ± 2.13874.82 ± 2.166
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.1872LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.3994LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.0422LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.3647LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.1729LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.2234LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.0950LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.4345LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.2840LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.6404LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.0550LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.4531LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryPain Treatment Satisfaction Scale (PTSS): Impact of Current Pain Medication

Impact of current pain medication response scale: 0 (worst possible response) to 100 (best possible response). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
Discharge (day 3 up to day 7 PS), Day 28 PS
Reported as:
Least squares mean · Units on a scale
Pain Treatment Satisfaction Scale (PTSS): Impact of Current Pain Medication
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
Discharge (n=139, 141, 140)72.73 ± 2.08066.28 ± 2.09972.82 ± 2.159
Day 28 (n=133, 135, 141)76.41 ± 2.18069.53 ± 2.18169.05 ± 2.156
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.9712LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.0112LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.0090LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.8650LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryQuality of Life Using EuroQol (EQ-5D) Health State Profile

Participant rated questionnaire assessed current health for 6 domains: mobility/self-care/ usual activities/pain/discomfort/anxiety and depression. Scoring developed by EuroQol Group assigned a utility value for each domain in the profile. Scores ranged from 1 better health (no problems) to 3 worst health (eg, "confined to bed"). Score transformed and resulted in a total score range -0.594 to 1.000; higher score=better health state. Health profile scores estimated using Dolan computational algorithms 1997 and 2001. LS Means adjusted for treatment/pooled center/salpingo-oophorectomy strata.

Time frame:
Discharge (day 3 up to day 7 PS) and day 28 PS
Reported as:
Least squares mean · Units on a scale
Quality of Life Using EuroQol (EQ-5D) Health State Profile
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
EQ-5D 1997, Discharge (n=138, 141, 138)0.57 ± 0.0210.61 ± 0.0210.58 ± 0.022
EQ-5D 1997, Day 28 (n=140, 143, 142)0.81 ± 0.0140.78 ± 0.0140.78 ± 0.014
EQ-5D 2001, Discharge (n=138, 141, 138)0.59 ± 0.0180.62 ± 0.0180.60 ± 0.019
EQ-5D 2001, Day 28 (n=140, 143, 142)0.81 ± 0.0140.78 ± 0.0140.78 ± 0.014
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.8914LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.2214LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.1008LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.9135LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.5609LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.4047LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.1663LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.8364LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryTime to Meet Hospital Discharge Criteria

Mean time from end of surgery to meet protocol defined hospital discharge criteria: participant no longer received parental opioids, was able to dress and mobilize without assistance, and had normal intake of food and fluids.

Time frame:
Day 1 up to Day 7 PS
Reported as:
Mean · Hours
Time to Meet Hospital Discharge Criteria
HoursPregabalin 150mgPregabalin 300 mgPlacebo
Time to Meet Hospital Discharge Criteria57.670 ± 2.82960.751 ± 2.67858.745 ± 2.786
Statistical analysis
  • Pregabalin 150mg vs Placebo · Log Rank · p = 0.7218
  • Pregabalin 300 mg vs Placebo · Log Rank · p = 0.4425
SecondaryTime to Actual Discharge

Mean time from end of surgery to actual hospital discharge. Participant was expected to remain at the hospital for a minimum of 2 days following surgery.

Time frame:
Day 1 up to Day 7 PS
Reported as:
Mean · Hours
Time to Actual Discharge
HoursPregabalin 150mgPregabalin 300 mgPlacebo
Time to Actual Discharge79.339 ± 2.54785.221 ± 3.93578.740 ± 2.441
Statistical analysis
  • Pregabalin 150mg vs Placebo · Log Rank · p = 0.7889
  • Pregabalin 300 mg vs Placebo · Log Rank · p = 0.1565
Other pre-specifiedNeuropathic Pain Symptom Inventory (NPSI)

Pain characteristics in participants who reported pain (mBPI-sf, NPSI); NPSI a participant rated questionnaire to evaluate different symptoms of neuropathic pain, burning spontaneous pain, pressing spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dysesthesia at discharge. NPSI Total Score ranged from 0 to 0.5; NPSI subscales pain ranged from 0 (no pain) to 10 (worst pain). LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
Discharge (day 3 up to day 7 PS)
Reported as:
Least squares mean · Units on a scale
Neuropathic Pain Symptom Inventory (NPSI)
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
Total subscale(n=132, 131, 136)0.073 ± 0.00570.070 ± 0.00570.076 ± 0.0058
Burning Spontaneous subscale (n=139, 145, 143)1.86 ± 0.2351.80 ± 0.2311.75 ± 0.235
Pressing Spontaneous subscale (n=139, 145, 143)1.74 ± 0.1661.60 ± 0.1641.57 ± 0.168
Paroxysmal pain subscale (n=138, 140, 143)1.08 ± 0.1550.95 ± 0.1541.18 ± 0.156
Evoked Pain subscale (n=134, 135, 142)2.14 ± 0.1772.27 ± 0.1772.27 ± 0.175
Paresthesia/dysesthesia (n=136, 140, 141)0.46 ± 0.1290.67 ± 0.1270.91 ± 0.128
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.6211LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.3687LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.7078LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.8696LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.4320LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.8843LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.6215LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.2722LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.5500LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.9942LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.0075LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1464LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
SecondaryIncidence of Chronic Post-operative Pain

Chronic post-operative pain as a result of abdominal hysterectomy as reported by participants on PS questionaire of pain within last 24 hours in area affected by surgery.

Time frame:
3 and 6 Months PS
Reported as:
Number · Percentage of participants
Incidence of Chronic Post-operative Pain
Percentage of participantsPregabalin 150mgPregabalin 300 mgPlacebo
Months 3 PS (n =136, 127, 138)12.517.310.1
Months 6 PS (n =138, 127, 141)6.56.34.3
Statistical analysis
  • Pregabalin 150mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.9877p-values are derived from CMH test adjusted for pooled centers and salpingo-oophorectomy strata
  • Pregabalin 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1334p-values are derived from CMH test adjusted for pooled centers and salpingo-oophorectomy strata
  • Pregabalin 150mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3566p-values are derived from CMH test adjusted for pooled centers and salpingo-oophorectomy strata
  • Pregabalin 300 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.6262p-values are derived from CMH test adjusted for pooled centers and salpingo-oophorectomy strata
SecondaryTotal Clinically Meaningful Event (CME) Score

Total CME score calculated by summing the number of Clinically Meaningful Events (CMEs) across symptoms. CME for each symptom will be defined using the Opioid-Related Symptom Distress Scale (OR-SDS) a participant rated scale of symptoms within the last 24 hours. Total CME score could range from 0 to 9. LS Means adjusted for treatment, pooled center and salpingo-oophorectomy strata.

Time frame:
Surgery Day, Day 1, 2, 3, 4, 5 PS, Discharge (day 3 up to day 7 PS), Day 7, 14, 28 PS
Reported as:
Least squares mean · Units on a scale
Total Clinically Meaningful Event (CME) Score
Units on a scalePregabalin 150mgPregabalin 300 mgPlacebo
Surgery Day (n=26, 25, 32)0.9 ± 0.290.8 ± 0.300.9 ± 0.26
Day 1 PS (n=148, 147, 154)1.1 ± 0.131.1 ± 0.131.2 ± 0.13
Day 2 PS (n=108, 116, 114)0.6 ± 0.120.6 ± 0.120.7 ± 0.12
Day 3 PS (n=38, 36, 32)0.5 ± 0.190.7 ± 0.170.3 ± 0.19
Day 4 PS (n=14, 16, 11)0.0 ± 0.190.4 ± 0.150.3 ± 0.22
Day 5 PS (n=5, 9, 6)0.4 ± 0.190.1 ± 0.130.3 ± 0.18
Discharge (n=133, 132, 133)0.4 ± 0.090.4 ± 0.090.3 ± 0.09
Day 7 PS (n=119, 117, 120)0.2 ± 0.060.4 ± 0.060.2 ± 0.06
Day 14 PS (n=119, 116, 124)0.1 ± 0.060.2 ± 0.060.1 ± 0.06
Day 28 PS (n=129, 135, 136)0.0 ± 0.060.2 ± 0.060.2 ± 0.06
Statistical analysis
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.9463LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.7347LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.4132LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.4929LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.6003LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.9343LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.3838LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.1351LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.3343LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.7948LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.8090LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.4035LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.6009LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.7597LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.7804LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.0463LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.4951LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.3030LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 150mg vs Placebo · ANOVA · p = 0.0104LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.
  • Pregabalin 300 mg vs Placebo · ANOVA · p = 0.6978LS Means from ANOVA model with terms of treatment, pooled center and salpingo-oophorectomy strata.

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin 150mg—9/161 (5.6%)125/161 (77.6%)
Pregabalin 300 mg—11/166 (6.6%)128/166 (77.1%)
Placebo—15/167 (9%)124/167 (74.3%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventPregabalin 150mgPregabalin 300 mgPlacebo
Postoperative wound infectionInfections and infestations2/1611/1661/167
Abdominal painGastrointestinal disorders1/1610/1661/167
GastritisGastrointestinal disorders1/1610/1660/167
IleusGastrointestinal disorders1/1610/1660/167
Umbilical herniaGastrointestinal disorders1/1610/1660/167
PyrexiaGeneral disorders1/1611/1661/167
Post procedural haematomaInjury, poisoning and procedural complications1/1611/1660/167
Postoperative ileusInjury, poisoning and procedural complications1/1610/1660/167
Liver function test abnormalInvestigations1/1610/1660/167
Oxygen saturation decreasedInvestigations1/1610/1660/167
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPregabalin 150mgPregabalin 300 mgPlacebo
NauseaGastrointestinal disorders67/16160/16676/167
DizzinessNervous system disorders51/16152/16637/167
ConstipationGastrointestinal disorders46/16149/16645/167
FatigueGeneral disorders38/16146/16634/167
SomnolenceNervous system disorders39/16139/16636/167
VomitingGastrointestinal disorders33/16120/16630/167
PyrexiaGeneral disorders31/16129/16624/167
Disturbance in attentionNervous system disorders24/16130/16623/167
HeadacheNervous system disorders27/16123/16619/167
PruritusSkin and subcutaneous tissue disorders27/16122/16626/167

Baseline characteristics

Age, Customized
Age, Customized(participants)Pregabalin 150mgPregabalin 300 mgPlaceboTotal
25-44 years777688241
45-70 years849079253
Unspecified1427
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin 150mgPregabalin 300 mgPlaceboTotal
Female162170169501
Male0000
08

Study locations

42 sites
  • Pfizer Investigational Site
    Mobile, Alabama 36608, United States
  • Pfizer Investigational Site
    Glendale, Arizona 85308, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85020, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85023, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85027, United States
  • Pfizer Investigational Site
    Glendale, California 91206, United States
  • Pfizer Investigational Site
    Pasadena, California 91105, United States
  • Pfizer Investigational Site
    Miami, Florida 33136-1096, United States
  • Pfizer Investigational Site
    Miami, Florida 33136, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15232, United States
  • Pfizer Investigational Site
    Houston, Texas 77024, United States
  • Pfizer Investigational Site
    Houston, Texas 77054, United States
  • Pfizer Investigational Site
    Calgary, Alberta T2N 2T9, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2X 3J4, Canada
  • Pfizer Investigational Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Pfizer Investigational Site
    Praha 5, 150 06, Czechia
  • Pfizer Investigational Site
    Kowloon, 0, Hong Kong
  • Pfizer Investigational Site
    Shatin, Hong Kong
  • Pfizer Investigational Site
    Johannesburg, Gauteng 1829, South Africa
  • Pfizer Investigational Site
    Krugersdorp, Gauteng 1752, South Africa
  • Pfizer Investigational Site
    Pretoria, Gauteng 0157, South Africa
  • Pfizer Investigational Site
    Newcastle, KwaZulu Natal 2940, South Africa
  • Pfizer Investigational Site
    Ladysmith, KZN 3370, South Africa
  • Pfizer Investigational Site
    Cape Town, Western Cape 7500, South Africa
  • Pfizer Investigational Site
    Parktown, 2193, South Africa
  • Pfizer Investigational Site
    Cadiz, 11009, Spain
  • Pfizer Investigational Site
    Madrid, 28031, Spain
  • Pfizer Investigational Site
    Madrid, 28046, Spain
  • Pfizer Investigational Site
    Valencia, 46010, Spain
  • Pfizer Investigational Site
    Lund, 221 85, Sweden
  • Pfizer Investigational Site
    Orebro, 701 85, Sweden
  • Pfizer Investigational Site
    Stockholm, 182 88, Sweden
  • Pfizer Investigational Site
    Bangkoknoi, Bangkok 10700, Thailand
  • Pfizer Investigational Site
    Muang, Chiang Mai 50200, Thailand
  • Pfizer Investigational Site
    Muang, Khon Kaen 40002, Thailand
  • Pfizer Investigational Site
    Leicester, Leicestershire LE1 5WW, United Kingdom
  • Pfizer Investigational Site
    Edinburgh, Scotland EH16 4SA, United Kingdom
  • Pfizer Investigational Site
    Birmingham, United Kingdom
  • Pfizer Investigational Site
    Liverpool, L8 7SS, United Kingdom
  • Pfizer Investigational Site
    Livingstone, EH54 6PP, United Kingdom
09

References and documents

Publications

  • Singla NK, Chelly JE, Lionberger DR, Gimbel J, Sanin L, Sporn J, Yang R, Cheung R, Knapp L, Parsons B. Pregabalin for the treatment of postoperative pain: results from three controlled trials using different surgical models. J Pain Res. 2014 Dec 23;8:9-20. doi: 10.2147/JPR.S67841. eCollection 2015. PubMed 25565885 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of May 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2007
First posted
May 3, 2007
Start
Jun 2007
Primary completionActual
May 2010
CompletionActual
Oct 2010
Results first posted
May 26, 2011
Last update
Feb 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00468845
Responsible party
Sponsor
First posted
May 3, 2007
Start date
Jun 2007
Primary completion
May 2010
Completion
Oct 2010
Results posted
May 26, 2011
Last update
Feb 10, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion